Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.50
+1.6212.58%
Post-market: 14.870.3700+2.55%19:59 EDT
Volume:12.43M
Turnover:174.90M
Market Cap:1.43B
PE:-2.49
High:14.58
Open:13.22
Low:13.20
Close:12.88
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:2.64
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.90
PE(LYR):-2.49

Loading ...

Ultragenyx Pharmaceutical (RARE) Stock Jumps 9% on Accelerated FDA Approval

TIPRANKS
·
Aug 20

Sector Update: Healthcare

MT Newswires Live
·
Aug 20

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Ultragenyx Pharmaceutical (RARE) and Cytokinetics (CYTK)

TIPRANKS
·
Aug 20

Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Aug 20

U.S. Stocks on the MOVE-Walmart, Atour Lifestyle, Wolfspeed

Reuters
·
Aug 20

Ultragenyx Pharmaceutical Shares up 8.6% Premarket After Securing FDA Nod for Rare Metabolic Disorder Gene Therapy

THOMSON REUTERS
·
Aug 20

Ultragenyx price target raised to $83 from $81 at Canaccord

TIPRANKS
·
Aug 20

Ultragenyx Pharma Price Target Raised to $103.00/Share from $96.00 by Cantor Fitzgerald

Dow Jones
·
Aug 20

Ultragenyx price target raised to $58 from $45 at Citi

TIPRANKS
·
Aug 20

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 20

FDA Grants Ultragenyx Accelerated Approval for Genglycos in GSDIa Patients 8 and Older

Reuters
·
Aug 20

Ultragenyx announces FDA accelerated approval of Genglycos

TIPRANKS
·
Aug 20

Ultragenyx's Gene Therapy for Rare Metabolic Disorder Secures US FDA Nod

Reuters
·
Aug 20

Ultragenyx Pharmaceutical - Genglycos to be Available Through National Network of Qualified Treatment Centers

THOMSON REUTERS
·
Aug 20

Ultragenyx Announces U.S. FDA Approval of Genglycos™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (Gsdia)

THOMSON REUTERS
·
Aug 20

Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks

Simply Wall St.
·
Aug 19

Binance flags 5 tokens as possible delisting risks

cryptonews
·
Aug 12

Ultragenyx Pharmaceutical: Will Grant Esjay a Non-Exclusive, Royalty-Free License to Market Its Generic Version of Dojolvi Beginning January 1, 2033

THOMSON REUTERS
·
Aug 11

Ultragenyx Pharmaceutical - Co and Bri Settle Dojolvi Patent Litigation with Esjay Pharma - SEC Filing

THOMSON REUTERS
·
Aug 11